share_log

Acrivon Therapeutics (NASDAQ:ACRV) Stock Price Up 1.2%

Acrivon Therapeutics (NASDAQ:ACRV) Stock Price Up 1.2%

Acrivon Therapeutics(纳斯达克股票代码:ACRV)股价上涨1.2%
Defense World ·  2023/02/02 03:32

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Rating) rose 1.2% during mid-day trading on Wednesday . The company traded as high as $18.96 and last traded at $16.40. Approximately 21,738 shares were traded during mid-day trading, an increase of 153% from the average daily volume of 8,588 shares. The stock had previously closed at $16.20.

周三午盘交易中,阿里冯治疗公司(纳斯达克代码:ACRV-GET评级)的股价上涨1.2%。该公司股价一度高达18.96美元,最新报16.40美元。午盘成交量约为21,738股,较日均成交量8,588股增加153%。该股此前收盘价为16.20美元。

Analyst Ratings Changes

分析师评级发生变化

ACRV has been the subject of a number of research analyst reports. Jefferies Financial Group initiated coverage on Acrivon Therapeutics in a research note on Monday, December 12th. They issued a "buy" rating and a $17.00 target price for the company. Cowen started coverage on Acrivon Therapeutics in a research note on Monday, December 12th. They issued an "outperform" rating for the company. Cowen started coverage on Acrivon Therapeutics in a research note on Monday, December 12th. They set an "outperform" rating for the company. Finally, Piper Sandler started coverage on Acrivon Therapeutics in a research note on Sunday, December 11th. They set an "overweight" rating and a $25.00 price objective for the company.

ACRV已经成为许多研究分析师报告的主题。杰富瑞金融集团在12月12日星期一的一份研究报告中发起了对Acrivon治疗的报道。他们对该公司的评级为买入,目标价为17.00美元。考恩在12月12日星期一的一份研究报告中开始报道Acrivon治疗公司。他们对该公司的评级为“跑赢大盘”。考恩在12月12日星期一的一份研究报告中开始报道Acrivon治疗公司。他们为该公司设定了“跑赢大盘”的评级。最后,Piper Sandler在12月11日星期日的一份研究报告中开始报道Acrivon治疗公司。他们为该公司设定了“增持”评级和25.00美元的目标价。

Get
到达
Acrivon Therapeutics
阿克瑞丰治疗公司
alerts:
警报:

Acrivon Therapeutics Stock Up 1.2 %

Acrivon Treeutics股价上涨1.2%

The firm's 50 day moving average price is $12.62.

该公司的50日移动均线价格为12.62美元。

Acrivon Therapeutics (NASDAQ:ACRV – Get Rating) last posted its earnings results on Thursday, December 15th. The company reported ($5.17) EPS for the quarter, missing analysts' consensus estimates of ($2.44) by ($2.73). Analysts expect that Acrivon Therapeutics, Inc. will post -4.33 earnings per share for the current year.
阿里冯治疗公司(纳斯达克代码:ACRV-GET评级)最近一次公布财报是在12月15日星期四。该公司公布本季度每股收益为5.17美元,低于分析师普遍预期的2.44美元和2.73美元。分析师预计,Acrivon治疗公司本年度的每股收益将达到4.33美元。

Insider Activity

内幕活动

In other news, Director Ra Capital Management, L.P. purchased 3,389,500 shares of Acrivon Therapeutics stock in a transaction dated Thursday, November 17th. The shares were purchased at an average price of $12.50 per share, with a total value of $42,368,750.00. Following the transaction, the director now owns 4,384,206 shares in the company, valued at $54,802,575. The purchase was disclosed in a document filed with the SEC, which is available through this link. In other news, major shareholder Ltd Chione bought 400,000 shares of the business's stock in a transaction on Thursday, November 17th. The shares were bought at an average price of $12.50 per share, with a total value of $5,000,000.00. Following the completion of the transaction, the insider now directly owns 3,856,597 shares in the company, valued at $48,207,462.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ra Capital Management, L.P. bought 3,389,500 shares of the business's stock in a transaction on Thursday, November 17th. The stock was purchased at an average cost of $12.50 per share, for a total transaction of $42,368,750.00. Following the transaction, the director now owns 4,384,206 shares of the company's stock, valued at $54,802,575. The disclosure for this purchase can be found here.

其他新闻方面,董事Ra Capital Management,L.P.在一笔日期为11月17日(星期四)的交易中购买了3,389,500股阿克瑞丰治疗公司的股票。这些股票是以每股12.50美元的平均价格购买的,总价值为42,368,750.00美元。交易完成后,董事现在拥有该公司4384,206股,价值54,802,575美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过这个环节。在其他新闻方面,大股东奇奥在11月17日星期四的一笔交易中购买了40万股该公司的股票。这些股票是以每股12.50美元的平均价格购买的,总价值为5,000,000.00美元。交易完成后,这位内部人士现在直接拥有该公司3856,597股,价值48,207,462.50美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过这个环节。此外,董事在11月17日(星期四)的一次交易中购买了3389,500股该公司的股票。该股票是以每股12.50美元的平均成本购买的,总交易额为42,368,750.00美元。交易完成后,董事现在拥有4384,206股该公司股票,价值54,802,575美元。关于这次购买的披露可以找到这里.

Hedge Funds Weigh In On Acrivon Therapeutics

对冲基金对Acrivon Treeutics的看法

An institutional investor recently bought a new position in Acrivon Therapeutics stock. Bank of Montreal Can purchased a new position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 42,444 shares of the company's stock, valued at approximately $545,000. Bank of Montreal Can owned approximately 0.20% of Acrivon Therapeutics as of its most recent SEC filing. Institutional investors own 63.82% of the company's stock.

一家机构投资者最近购买了Acrivon治疗公司股票的新头寸。蒙特利尔银行最近提交给美国证券交易委员会的表格13F显示,该行可以在第四季度购买阿里冯治疗公司(纳斯达克:ACRV-GET Rating)的新股票头寸。该机构投资者购买了42,444股该公司股票,价值约545,000美元。截至最近提交给美国证券交易委员会的文件,蒙特利尔银行可以拥有阿里冯治疗公司约0.20%的股份。机构投资者持有该公司63.82%的股份。

Acrivon Therapeutics Company Profile

Acrivon治疗公司简介

(Get Rating)

(获取评级)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).

Acrivon治疗公司是一家临床阶段的生物制药公司,该公司致力于开发精确肿瘤学药物,通过利用其基于蛋白质组学的患者响应者识别平台Acrivon Predictive Precision Protetics(AP3),将其与预测其肿瘤对特定药物敏感的患者相匹配。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
  • Bed Bath & Beyond Is Circling the Drain
  • Allegro Microsystems Is A Well-Positioned Semiconductor Stock
  • Scotts Miracle-Gro Hits Bottom, Reversal In Play
  • Altria is a Great Recession Stock, Long-Term Outlook Uncertain
  • Novavax Shares Jumped in January While Others Slipped
  • 免费获取StockNews.com关于Acrivon治疗公司(ACRV)的研究报告
  • Bed Bath&Beyond正在绕着排水沟走
  • Allegro MicroSystems是一只定位良好的半导体股票
  • 斯科特奇迹-Gro触底,比赛逆转
  • 奥驰亚是一只大衰退的股票,长期前景不确定
  • Novavax的股价在1月份大幅上涨,而其他股票则出现下滑

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

获得Acrivon治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acrivon Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发